Bristol Myers Squibb received regulatory approval to expand the indication for its CAR‑T therapy Breyanzi to include third‑line marginal zone lymphoma, marking the first CAR‑T approval for this rare, indolent non‑Hodgkin lymphoma subtype. The label expansion follows submission datasets reviewed by regulators and provides a new cellular therapy option for patients with limited lines of effective treatment. Brokers and clinicians noted the approval as a measured extension of CAR‑T utility into less aggressive hematologic malignancies. Sources: company announcement and regulatory filings.